Clinical assessment of moderate-dose glucocorticoid in the treatment of recurrence of primary nephrotic syndrome in children: a prospective randomized controlled trial.
10.7499/j.issn.1008-8830.2111133
- Author:
Juan TU
1
;
Chao-Ying CHEN
1
;
Hai-Yun GENG
1
;
Hua-Rong LI
1
;
Hua XIA
1
;
Yuan LIN
1
;
Tian-Tian LIN
1
;
Jin-Shan SUN
1
Author Information
1. Department of Nephrology, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing 100020, China.
- Publication Type:Randomized Controlled Trial
- Keywords:
Child;
Glucocorticoid;
Nephrotic syndrome;
Recurrence
- MeSH:
Child;
Glucocorticoids/therapeutic use*;
Humans;
Nephrotic Syndrome/drug therapy*;
Prednisone/adverse effects*;
Prospective Studies;
Remission Induction
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(5):466-471
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To study the clinical effect and adverse drug reactions of different doses of glucocorticoid (GC) in the treatment of children with recurrence of steroid-sensitive nephrotic syndrome (SSNS).
METHODS:A total of 67 children who were hospitalized and diagnosed with SSNS recurrence in the Department of Nephrology, Children's Hospital, Capital Institute of Pediatrics, from November 2017 to December 2019 were enrolled. They were randomly divided into a moderate-dose GC group (32 children) and a full-dose GC group (35 children). The two groups were compared in terms of urinary protein clearance, recurrence rate within 6 months, and incidence rate of GC-associated adverse reactions.
RESULTS:There was no significant difference in the urinary protein clearance rate between the moderate-dose GC and full-dose GC groups (91% vs 94%, P>0.05). There was also no significant difference in the recurrence rate within 6 months between the two groups (41% vs 36%, P>0.05). At 6 months of follow-up, compared with the full-dose GC group, the moderate-dose GC group had a significantly lower cumulative dose of prednisone [(87±18) mg/kg vs (98±16) mg/kg, P=0.039] and a significantly lower proportion of children with an abnormal increase in body weight (6% vs 33%, P=0.045). The logistic regression analysis showed that prednisone dose ≥10 mg/alternate day at enrollment was a risk factor for recurrence within 6 months in children with SSNS (P=0.018).
CONCLUSIONS:For children with SSNS recurrence, moderate-dose GC has similar effects to full-dose GC in the remission induction rate and the recurrence rate within 6 months, with a lower cumulative dose and fewer GC-associated adverse reactions within 6 months than full-dose GC.
